WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for ...

AstraZeneca has put a lot of resources behind its aging blood thinner Brilinta, hoping to keep the anticoagulant's place in doctors' minds fresh for years to come. With a suite of new data and ...

The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca's struggling oral antiplatelet drug. The collaboration is the first stage of "a global ...

Investigations related to products or pipeline candidates by regulatory authorities are a major overhang for companies and create uncertainty until the issue is resolved. Earlier this week, ...

The Food and Drug Administration (FDA) has approved Brilinta (ticagrelor; AstraZeneca) tablets at a new 60mg dose for use in patients with a history of heart attack beyond 12 months. The Food and Drug ...

Data from the study indicated no statistically significant difference between the pre-hospital and in-hospital study arms in terms of pre-percutaneous coronary intervention (PCI) procedural ...

(CBS/AP) The FDA has approved the blood thinner Brilinta, and that means there's an alternative to the blockbuster pill Plavix for patients who have clogged arteries associated with a condition known ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with ...

The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events. The Food and Drug ...

Please read full Prescribing Information, including Boxed WARNINGS, and Medication Guide. Additional information can be found at www.brilintatouchpoints.com. (Photo: AstraZeneca) Complete the Course ...

AstraZeneca plcAZN announced disappointing top-line data from the SOCRATES study on its heart drug Brilinta/Brilique (ticagrelor). The study evaluated the efficacy and safety of Brilinta (90 mg, twice ...

Detailed results from a prespecified subgroup (n=2,351) analysis of the positive THALES Phase III trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin ...